Original Article
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
N Engl J Med 2010; 362:1675-1685May 6, 2010
- Abstract
Background
Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no established treatment for this disease.
Methods
We randomly assigned 247 adults with nonalcoholic steatohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96 weeks. The primary outcome was an improvement in histologic features of nonalcoholic steatohepatitis, as assessed with the use of a composite of standardized scores for steatosis, lobular inflammation, hepatocellular ballooning, and fibrosis. Given the two planned primary comparisons, P values of less than 0.025 were considered to indicate statistical significance.
Results
Vitamin E therapy, as compared with placebo, was associated with a significantly higher rate of improvement in nonalcoholic steatohepatitis (43% vs. 19%, P=0.001), but the difference in the rate of improvement with pioglitazone as compared with placebo was not significant (34% and 19%, respectively; P=0.04). Serum alanine and aspartate aminotransferase levels were reduced with vitamin E and with pioglitazone, as compared with placebo (P<0.001 for both comparisons), and both agents were associated with reductions in hepatic steatosis (P=0.005 for vitamin E and P<0.001 for pioglitazone) and lobular inflammation (P=0.02 for vitamin E and P=0.004 for pioglitazone) but not with improvement in fibrosis scores (P=0.24 for vitamin E and P=0.12 for pioglitazone). Subjects who received pioglitazone gained more weight than did those who received vitamin E or placebo; the rates of other side effects were similar among the three groups.
Conclusions
Vitamin E was superior to placebo for the treatment of nonalcoholic steatohepatitis in adults without diabetes. There was no benefit of pioglitazone over placebo for the primary outcome; however, significant benefits of pioglitazone were observed for some of the secondary outcomes. (ClinicalTrials.gov number, NCT00063622.)
Media in This Article
Figure 1
Screening, Randomization, and Follow-up of Study Subjects.Figure 2
Changes from Baseline in Aminotransferase Levels, Insulin Resistance, and Weight, According to Study Group.Article Activity
- Article
Nonalcoholic steatohepatitis is a common liver disease that is characterized histologically by hepatic steatosis, lobular inflammation, and hepatocellular ballooning1,2; it can progress to cirrhosis in up to 15% of patients.3,4 There is currently no therapy that is of proven benefit for nonalcoholic steatohepatitis. The disease is closely associated with insulin resistance and features of the metabolic syndrome such as obesity, hypertriglyceridemia, and type 2 diabetes. 5,6 In addition to insulin resistance, oxidative stress has been implicated as a key factor contributing to hepatic injury in patients with nonalcoholic steatohepatitis.6,7 Thus, both insulin resistance and oxidative stress are attractive targets for therapy in patients with this disease.
Several pilot studies have provided evidence that insulin sensitizers such as thiazolidinediones and antioxidants such as vitamin E improve clinical and histologic features of nonalcoholic steatohepatitis.8-14 The medical evidence of a benefit, however, is limited, because these studies had small samples and were performed at single centers. Moreover, a recent multicenter trial showed a reduction in hepatic steatosis but no improvement in markers of cell injury after a year of rosiglitazone therapy.15 The value of these drugs remains uncertain.
The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) was established by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to address unmet research needs in the field. As a part of this mandate, the NASH CRN conducted the Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis (PIVENS) trial, a phase 3, multicenter, randomized, placebo-controlled, double-blind clinical trial of pioglitazone or vitamin E for the treatment of adults without diabetes who had biopsy-confirmed nonalcoholic steatohepatitis.
Methods
Study Oversight
The PIVENS protocol and consent forms were designed by a subcommittee and approved by the steering committee of the CRN (see the Appendix). The study was approved by the review board at each participating center, and all subjects gave written informed consent. The study was conducted by site investigators, and data were gathered by specifically trained personnel. The data were analyzed at the data coordinating center and were reviewed by both the investigators and an independent data and safety monitoring board. The manuscript was written by a CRN subcommittee and approved by the members of the steering committee, who assume responsibility for the integrity of the data and the overall content of the manuscript.
Study Design
The trial design and rationale for the PIVENS trial have been described previously.16 This trial focused on adults without diabetes who had nonalcoholic steatohepatitis. Adults with diabetes were excluded because it was unclear whether they would have the same responses to therapy as would adults without diabetes and because it was possible that changes in antidiabetic therapy might confound the analysis of data both from subjects with diabetes and from those without diabetes. All subjects underwent a liver biopsy within 6 months before randomization.
Steatohepatitis was categorized as absent, possible, or definite.17 Disease activity was assessed with the use of the nonalcoholic fatty liver disease activity score, which is based on a standardized grading system for steatosis (on a scale of 0 to 3), lobular inflammation (on a scale of 0 to 3), and hepatocellular ballooning (on a scale of 0 to 2), with higher scores indicating increasing severity).17 The specific inclusion criteria were definite or possible steatohepatitis with an activity score of 5 or more, or definite steatohepatitis (confirmed by two pathologists) with an activity score of 4. A score of at least 1 for hepatocellular ballooning was required in all cases. Although eligibility was determined by the pathologist at each site from an assessment of tissue sections prepared locally, the final analysis was based on review by a pathology committee of deeper cuts, prepared centrally, from the biopsy specimens obtained at baseline and at the end of treatment. Members of the pathology committee who performed the final analysis were unaware of the study-group assignments.
Exclusion criteria were alcohol consumption of more than 20 g per day in the case of women and more than 30 g per day in the case of men for at least 3 consecutive months during the previous 5 years, as assessed with the use of the Lifetime Drinking History questionnaire of Skinner et al.18 and the self-administered Alcohol Use and Disorders Identification Test (AUDIT).19 Subjects were also excluded if they had cirrhosis, hepatitis C or other liver diseases, or heart failure (New York Heart Association class II to IV), or if they were receiving drugs known to cause steatohepatitis.
Both at the initial evaluation and at the completion of treatment 96 weeks later, subjects underwent an assessment of body weight, height, and waist and hip circumferences, and blood samples were obtained for routine biochemical tests and assessment of fasting levels of lipids, glucose, and insulin. Body composition was assessed with the use of dual-energy x-ray absorptiometry. The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) was administered for the assessment of quality of life.
Randomization and Treatment Groups
Subjects who met all eligibility criteria and provided written informed consent were randomly assigned to one of three groups for 96 weeks of study treatment: a group receiving pioglitazone (at a dose of 30 mg once daily) and a vitamin E–like placebo (once daily), a group receiving vitamin E (800 IU, natural form, once daily) and a pioglitazone-like placebo (once daily); or a group receiving a pioglitazone-like placebo (once daily) and a vitamin E–like placebo (once daily). The 30-mg pioglitazone tablets (Actos) and similar-appearing placebo tablets were provided by Takeda Pharmaceuticals North America under a collaborative research and development agreement with the NIDDK. The 800-IU liquid soft-gelatin capsules of RRR-α-tocopherol (formerly known as d-α-tocopherol) vitamin E (Nature Made) and similar-appearing placebo soft-gelatin capsules were provided by Pharmavite under a clinical trial agreement with the NIDDK. Both Takeda and Pharmavite provided comments regarding the study design but were not involved in the writing of the protocol, the conduct of the trial, the decision-making with respect to the trial, or the analysis of the data. Both companies were shown a draft of the manuscript 30 days before it was submitted for publication but were not involved in the preparation of the manuscript. The doses were selected on the basis of previous phase 2 studies.9,13
Follow-up Visits
After randomization, subjects were followed according to a predetermined schedule for assessment of the safety and tolerability of the study drugs. Subjects were discouraged from adding other drugs that are used for nonalcoholic steatohepatitis to their regimen. All subjects were given a standardized set of pragmatic recommendations about lifestyle changes and diet. A liver biopsy was performed 96 weeks after randomization, after which the study drugs were discontinued. Subjects were then followed for an additional 24 weeks.
Primary and Secondary Outcomes
The primary outcome was an improvement in histologic findings, which required an improvement by 1 or more points in the hepatocellular ballooning score; no increase in the fibrosis score; and either a decrease in the activity score for nonalcoholic fatty liver disease to a score of 3 or less or a decrease in the activity score of at least 2 points, with at least a 1-point decrease in either the lobular inflammation or steatosis score.
Secondary outcomes included changes in the overall activity score for nonalcoholic fatty liver disease, as well as in individual component scores for steatosis, lobular inflammation, hepatocellular ballooning, and fibrosis, and changes in serum aminotransferase levels, anthropometric measures, and insulin resistance and lipid profiles. An additional secondary outcome was the change in health-related quality of life from baseline to the end of treatment, as assessed with the use of the SF-36.
Statistical Analysis
The primary analysis was an intention-to-treat analysis in which the proportions of subjects in each active-treatment group (pioglitazone and vitamin E) in whom there was improvement in nonalcoholic steatohepatitis were compared with the proportion of subjects in the placebo group in whom there was improvement. Comparisons were made with the use of the Mantel–Haenszel chi-square test, stratified according to clinical site. Subjects who did not undergo an end-of-treatment biopsy were classified as not having had improvement. Given the fact that there were two planned primary comparisons, Bonferroni-adjusted P values of less than 0.025 were considered to indicate statistical significance. The number of subjects who would need to be treated to achieve histologic improvement in one patient was calculated for the vitamin E and pioglitazone treatments. We analyzed secondary outcomes with the use of Fisher's exact test for binary outcomes and analysis-of-covariance models for continuous outcomes, regressing change from baseline to 96 weeks on treatment group and baseline value of the outcome variable in order to adjust comparisons of mean changes in secondary outcomes for the baseline value of the outcome variable.
The planned sample size was 240 subjects, with equal assignment to each of the three study groups (80 per group). We estimated that with this sample size, the study would have 90% power to detect an absolute difference in the rate of improvement in nonalcoholic steatohepatitis of 26 percentage points, with a two-sided type 1 error of 0.025.16 An independent data and safety monitoring board appointed by the NIDDK monitored the results semiannually; O'Brien–Fleming statistical stopping guidelines were used, with one interim analysis for efficacy performed midway through the trial.
Results
Study Subjects
Subjects were enrolled in the trial between January 2005 and January 2007 and were treated and followed for 96 weeks (Figure 1Figure 1
Screening, Randomization, and Follow-up of Study Subjects.). Of the 247 subjects who underwent randomization, 83 were assigned to receive placebo, 84 were assigned to receive vitamin E, and 80 were assigned to receive pioglitazone. The three groups were well matched with respect to demographic characteristics, clinical and laboratory data, and activity scores for nonalcoholic fatty liver disease (Table 1Table 1
Baseline Characteristics of the Study Subjects.). However, according to the planned, blinded, central analysis of liver-biopsy specimens, 17% of the subjects in the placebo group, 18% of those in the vitamin E group, and 28% of those in the pioglitazone group did not have hepatocellular ballooning on assessment of their initial biopsy specimen.Primary Outcome
A total of 90% of the subjects underwent an end-of-treatment liver biopsy at 96 weeks. Vitamin E therapy, as compared with placebo, was associated with a significantly higher rate of improvement in nonalcoholic steatohepatitis (43% vs. 19%, P=0.001; number needed to treat, 4.2), but the comparison of pioglitazone therapy with placebo did not reach the prespecified 0.025 level of significance for the primary outcome (34% vs. 19%, P=0.04; number needed to treat, 6.9) (Table 2Table 2
Primary Outcome and Changes in Histologic Features of the Liver after 96 Weeks of Treatment.).Given the subjectivity of histologic analysis, several sensitivity analyses were performed. If a finding of no worsening (rather than improvement) of hepatocellular ballooning was used as a criterion in the outcome measure, both active drugs were significantly associated with an improvement in histologic features of nonalcoholic steatohepatitis, as compared with placebo (placebo vs. vitamin E: 25% vs. 51% improvement, P<0.001; placebo vs. pioglitazone: 25% vs. 48%, P=0.003). When subjects who did not have hepatocellular ballooning initially, as assessed by central review, were excluded from the analyses, both active drug groups were associated with a significant improvement in histologic findings (placebo vs. vitamin E: 23% vs. 52% improvement, P<0.001; placebo vs. pioglitazone: 23% vs. 47%, P=0.002). An analysis of baseline factors to identify characteristics associated with a histologic response to either active treatment did not reveal any significant findings, and the data were consistent across all subgroups that were analyzed (Table 10 in the Supplementary Appendix, available with the full text of this article at NEJM.org).
Secondary Outcomes
Histologic Features
As compared with the placebo group, both active-treatment groups had a significant reduction in steatosis, lobular inflammation (Fig. 1 in the Supplementary Appendix), and the activity score for nonalcoholic fatty liver disease (Table 2). Although scores for hepatocellular ballooning were improved with vitamin E and with pioglitazone, only the improvement with vitamin E was significant (P=0.01). Fibrosis scores were not significantly improved with either active treatment. Steatohepatitis resolved in a greater proportion of subjects receiving either vitamin E or pioglitazone than in those receiving placebo, but the difference was significant only for those receiving pioglitazone (P=0.001) (Table 2).
Serum Enzyme Levels and Liver Test Results
There was an early and highly significant decrease in mean aspartate aminotransferase and alanine aminotransferase levels among subjects receiving vitamin E and among subjects receiving pioglitazone (Figure 2Figure 2
Changes from Baseline in Aminotransferase Levels, Insulin Resistance, and Weight, According to Study Group.). These changes occurred in the first 24 weeks and were sustained throughout the period in which the subjects were receiving treatment. Serum concentrations of alkaline phosphatase and γ-glutamyl transpeptidase also improved in the two active-drug groups, but bilirubin levels did not change significantly.Body Weight, Insulin Resistance, and Quality of Life
There was a significant improvement in insulin resistance only in the pioglitazone group, but that group was also the only group that had a significant mean weight gain (a mean increase of 4.7 kg at week 96, P<0.001 for the comparison with placebo) (Table 3Table 3
Changes in Serum Biochemical Levels, Metabolic Factors, and Quality of Life from Baseline to 96 Weeks.). These changes were noted by week 24, and the weight gain progressed over the course of the study. Although insulin resistance returned to the baseline value after discontinuation of pioglitazone, the associated weight gain was not reversed. Changes in quality of life, as assessed by the scores for both the mental and physical components of the SF-36, did not differ significantly between the vitamin E group or the pioglitazone group and the placebo group (Table 3).Adverse Events
With the exception of weight gain, the overall distribution of individual adverse events did not differ significantly across the study groups. There were 19 severe adverse events — 10 in the placebo group, 7 in the vitamin E group, and 2 in the pioglitazone group (see Table 3 in the Supplementary Appendix for details). A similar number of cardiovascular events occurred among subjects taking placebo (12 events), those taking vitamin E (12), and those taking pioglitazone (10). No cases of congestive heart failure were reported. The frequency of bone fractures was also similar across study groups: five in the placebo group, three in the vitamin E group, and three in the pioglitazone group. During the 96 weeks of the study, diabetes developed in four subjects who were receiving vitamin E but in none of the subjects who were receiving placebo or pioglitazone (P=0.12 for the comparison of vitamin E with placebo). Symptoms and signs of cirrhosis (thrombocytopenia, anasarca, and hyperbilirubinemia) developed in one patient in the vitamin E group who had had bridging hepatic fibrosis at entry, and that patient died of sepsis. No cases of serious hepatotoxicity requiring permanent discontinuation of the study drug were reported.
Discussion
The assessment of therapeutic agents for nonalcoholic steatohepatitis is a complex process. Because there are no validated biomarkers of response to treatment, one must rely on histologic assessment of a liver-biopsy specimen for this purpose. The activity score for nonalcoholic fatty liver disease quantifies the severity of steatosis, hepatocellular ballooning, and inflammation — the key histologic components of the disease.17 A decrease in their severity occurs with amelioration of the disease; however, the severity of these components (especially hepatic steatosis) may also decrease with progression of fibrosis to cirrhosis.20,21
To develop an outcome that was both quantifiable and clinically relevant, the requirements of an improvement in ballooning and no worsening of fibrosis were added to the requirement of a decrease in the nonalcoholic fatty liver disease activity score for the primary outcome. This makes it likely that the observed improvements with vitamin E are both statistically and clinically significant. These improvements are also concordant with those in previous small, pilot trials.12,13 These data cannot, however, be generalized to patients with diabetes or to those with cirrhosis, and additional clinical trials both to confirm these findings and to determine the generalizability of the data are warranted.
Although pioglitazone did not meet the prespecified significance level for the primary outcome, it was associated with highly significant reductions in steatosis, inflammation, and hepatocellular ballooning, as well as with improvements in insulin resistance and liver-enzyme levels (Table 2 and Figure 2). It also led to the resolution of steatohepatitis in a significant proportion of subjects. One possible reason for the failure to achieve the primary outcome with pioglitazone therapy, even though it significantly improved individual features of nonalcoholic steatohepatitis, is that more subjects in the pioglitazone group than in the vitamin E and placebo groups were classified as not having had ballooning, on the basis of the planned central review of deeper cuts of baseline biopsy specimens, and a reduction in ballooning was one of the criteria for the primary outcome. The discrepancies between the results of liver histologic assessments that were performed locally to determine eligibility and the results of assessments of deeper cuts of the same tissue block that were performed centrally to determine histologic baseline and outcome measures for use in the study analyses may have been due to interobserver variability, variable distribution of histologic findings in the different tissue sections, or a potential bias due to the unblinded nature of the local pathological review to determine eligibility.22-24
It is important not to overinterpret the data on adverse events in this trial because the study was not powered to test any safety-related hypotheses. The risk of bone fracture was not increased with pioglitazone25; however, the number of postmenopausal women included in the trial was too small to assess any potential effect. Although diabetes developed in subjects in the vitamin E group but not in subjects in the other two groups, only four subjects were affected, and this number is smaller than the number that would be expected in this patient population. Finally, cardiovascular events occurred with equal frequency in all three study groups, but, again, the trial was much too small to detect meaningful differences in the incidence of cardiovascular events.
Enthusiasm for the potential benefits of pioglitazone and vitamin E must be tempered by the finding that there was an improvement in histologic features in only 34% of the subjects who received pioglitazone and 43% of those who received vitamin E, and steatohepatitis resolved in only 47% and 36% of the subjects in those two groups, respectively. Neither agent was associated with a significant improvement in the mean fibrosis score after 96 weeks of treatment. There was also no significant reduction in portal inflammation, which has been linked to advanced disease.4,26 Given the certainty of relapse after discontinuation of the drug, it is likely that whichever drug is prescribed for nonalcoholic steatohepatitis, it will need to be taken indefinitely.13,27 The weight gain among the subjects receiving pioglitazone — which did not resolve after discontinuation of the drug — also detracts from its long-term usefulness. The unknown long-term potential for adverse events with vitamin E and pioglitazone therapies must be factored into the decision about whether to use these agents.25,28,29
The decision about which specific therapy to use for the treatment of nonalcoholic steatohepatitis should include a consideration of both the efficacy and the toxic effects of the therapy as compared with those of other available therapies. Preliminary studies provide a rationale for the use of lifestyle intervention, bariatric surgery, phlebotomy, and a variety of drugs. However, the usefulness of each of these therapeutic options has not been validated in rigorously performed, randomized, controlled trials. Our study provides such evidence for vitamin E and pioglitazone; however, this trial was not designed to compare vitamin E with pioglitazone, and no conclusions can be drawn about their relative efficacy.
In summary, the results of this trial of pioglitazone and vitamin E for the treatment of nonalcoholic steatohepatitis in adults without diabetes showed that vitamin E was superior to placebo and suggested that pioglitazone may also have efficacy. Although only subjects who received vitamin E met the criteria for the prespecified primary outcome measure, subjects who received pioglitazone had significant improvement in other important histologic features of nonalcoholic steatohepatitis.
Supported by grants (U01DK61718, U01DK61728, U01DK61731, U01DK61732, U01DK61734, U01DK61737, U01DK61738, U01DK61730, and U01DK61713) from the National Institutes of Health (NIH), by the intramural program of the National Cancer Institute, and by NIH General Clinical Research Center grants or Clinical and Translational Science Awards (UL1RR024989, UL1RR024128, M01RR000750, UL1RR024131, M01RR000827, UL1RR025014, and M01RR000065). Additional funding was provided by Takeda Pharmaceuticals North America through a Cooperative Research and Development Agreement with the NIH. The vitamin E softgels and matching placebo were provided by Pharmavite through a Clinical Trial Agreement with the NIH.
Dr. Sanyal reports receiving consulting fees from Exalenz, Takeda Pharmaceuticals North America, Norgine, Astellas, and Amylin, grant support from Intercept Pharmaceuticals, Gilead, Roche, Salix Pharmaceuticals, Sanofi-Aventis, Otsuka, and Orphan Therapeutics, and royalties from UpToDate; Dr. Neuschwander-Tetri, consulting fees from Gilead, Astellas, Amylin, Centocor, Vertex, and Sanofi-Aventis and reimbursements for travel or accommodations expenses from Astellas and Gilead; Dr. Kowdley, consulting fees from Gilead, Novartis, Bristol-Myers Squibb, and Vertex, gifts from Roche, honoraria from Bristol-Myers Squibb, Schering-Plough (now Merck), and Roche, lecture fees from Bristol-Myers Squibb, grant support from Intercept, Schering-Plough (now Merck), and royalties from UpToDate; Dr. Diehl, consulting fees and reimbursements for travel or accommodations from CellszDirect and Vertex, and grant support from Norgine and Gilead; Dr. Bass, consulting fees from Genentech and Norgine; and Dr. Chalasani, consulting fees from Gilead, Genentech, Amylin, Pfizer, Advanced Life Sciences, Metabasis (now Ligand Pharmaceuticals), AtheroGenics, Karo Bio, Debiovision, Eli Lilly, Johnson & Johnson, Teva Pharmaceuticals, Abbott, Norgine, Ockham, and Salix Pharmaceuticals, grant support from Gilead, Eli Lilly, Debiovision, and Monarch LifeSciences, reimbursements for travel and accommodations from Salix Pharmaceuticals, Gilead, Genentech, Advanced Life Sciences, Amylin, Metabasis (now Ligand Pharmaceuticals), AtheroGenics, Johnson & Johnson, Debiovision and Pfizer, and fees for serving on the data and safety monitoring board for Takeda and being named on patents pending for biomarkers of nonalcoholic steatohepatitis held by Indiana University. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0907929) was published on April 28, 2010, at NEJM.org.
Source Information
From Virginia Commonwealth University, Richmond (A.J.S.); Indiana University, Indianapolis (N.C.); Virginia Mason Medical Center, Seattle (K.V.K.); Case Western Reserve University, Cleveland (A.M.); Duke University, Durham, NC (A.M.D.); University of California San Francisco, San Francisco (N.M.B.); Saint Louis University (B.A.N.-T.) and Washington University (E.M.B.) — both in St. Louis; University of California San Diego, San Diego (J.E.L.); Johns Hopkins University, Baltimore (J.T., A.U., M.V.N., J.C.); and the National Cancer Institute (D.E.K.) and National Institute of Diabetes and Digestive and Kidney Diseases (J.H.H., P.R.R.) — both in Bethesda, MD.
Address reprint requests to Dr. Sanyal at MCV Box 980342, Richmond, VA 23298-0342, or at asanyal@mcvh-vcu.edu.
The members of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) are listed in the Appendix.
Appendix
Members of the Nonalcoholic Steatohepatitis Clinical Research Network are as follows. Steering Committee — J. Lavine (cochair), University of California San Diego; A. Sanyal (cochair), Virginia Commonwealth University; S. Abrams, Baylor College of Medicine; N. Bass, University of California San Francisco; N. Chalasani, Indiana University; A.M. Diehl, Duke University; K. Kowdley, Virginia Mason Medical Center; R. Loomba, University of California San Diego; A. McCullough, Case Western Reserve University; J. Molleston, Indiana University; K. Murray, University of Washington; P. Robuck, National Institute of Diabetes and Digestive and Kidney Diseases; P. Rosenthal, University of California San Francisco; B. Neuschwander-Tetri, Saint Louis University; J. Tonascia, Johns Hopkins University, Data Coordinating Center. Protocol Subcommittee — N. Chalasani, A. Sanyal, A. Unalp. Clinical centers enrolling subjects in the PIVENS trial — Case Western Reserve University and Cleveland Clinic Foundation — both in Cleveland: A. McCullough, D. Bringman, S. Dasarathy, K. Edwards, C. Hawkins, Y.-C. Liu, N. Rogers, R. Sargent; Duke University Medical Center, Durham, NC: A.M. Diehl, M. Abdelmalek, M. Gottfried, C. Guy, P. Killenberg, S. Kwan, Y.-P. Pan, D. Piercy, M. Smith; Indiana University School of Medicine, Indianapolis: N. Chalasani, P. Bhimalli, O.W. Cummings, A. Klipsch, L. Lee, J. Molleston, L. Ragozzino, R. Vuppalanchi; Saint Louis University, St. Louis: B.A. Neuschwander-Tetri, J. Derdoy, J. Hoffmann, D. King, J. Siegner, S. Stewart, J. Thompson, E. Brunt; University of California San Diego, San Diego: J.E. Lavine, C. Behling, L. Clark, J. Durelle, T. Hassanein, L. Petcharaporn, J.B. Schwimmer, C. Sirlin, T. Stein; University of California San Francisco, San Francisco: N.M. Bass, K. Bambha, L.D. Ferrell, D. Filipowski, R. Merriman, M. Pabst, M. Rosenthal, P. Rosenthal, T. Steel; Virginia Commonwealth University, Richmond: A.J. Sanyal, S. Boyett, M.J. Contos, M. Fuchs, A. Jones, V.A.C. Luketic, B. Sandhu, C. Sargeant, K. Selph, M. White; Virginia Mason Medical Center, Seattle: K.V. Kowdley, G. Gyurkey, J. Mooney, J. Nelson, S. Ackermann, C. Saunders, A. Stead, C. Wang, M. Yeh. Resource centers — National Cancer Institute, Bethesda, MD: D. Kleiner; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD: E. Doo, J. Everhart, J.H. Hoofnagle, P.R. Robuck (project scientist), L. Seeff; Johns Hopkins University Bloomberg School of Public Health (Data Coordinating Center), Baltimore: J. Tonascia, P. Belt, F. Brancati, J. Clark, R. Colvin, M. Donithan, M. Green, M. Isaacson, W. Kim, L. Miriel, A. Sternberg, A. Ünalp, M. Van Natta, I. Vaughn, L. Wilson, K. Yates.
- References
References
1
Browning JD ,Szczepaniak LS ,Dobbins R , et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395
CrossRef | Web of Science | Medline2
Ludwig J ,Viggiano TR ,McGill DB ,Oh BJ . Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438
Web of Science | Medline3
Adams LA ,Sanderson S ,Lindor KD ,Angulo P . The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-138
CrossRef | Web of Science | Medline4
Ekstedt M ,Franzen LE ,Mathiesen UL , et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873
CrossRef | Web of Science | Medline5
Marchesini G ,Brizi M ,Bianchi G , et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850
CrossRef | Web of Science | Medline6
Sanyal AJ ,Campbell-Sargent C ,Mirshahi F , et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192
CrossRef | Web of Science | Medline7
McClain CJ ,Mokshagundam SP ,Barve SS , et al. Mechanisms of non-alcoholic steatohepatitis. Alcohol 2004;34:67-79
CrossRef | Web of Science | Medline8
Belfort R ,Harrison SA ,Brown K , et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307
Full Text | Web of Science | Medline9
Promrat K ,Lutchman G ,Uwaifo GI , et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-196
CrossRef | Web of Science | Medline10
Caldwell SH ,Hespenheide EE ,Redick JA ,Iezzoni JC ,Battle EH ,Sheppard BL . A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525
CrossRef | Web of Science | Medline11
Neuschwander-Tetri BA ,Brunt EM ,Wehmeier KR ,Oliver D ,Bacon BR . Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-1017
CrossRef | Web of Science | Medline12
Sanyal AJ ,Mofrad PS ,Contos MJ , et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-1115
CrossRef | Web of Science | Medline13
Lavine JE . Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734-738
CrossRef | Web of Science | Medline14
Harrison SA ,Torgerson S ,Hayashi P ,Ward J ,Schenker S . Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-2490
CrossRef | Web of Science | Medline15
Ratziu V ,Giral P ,Jacqueminet S , et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100-110
CrossRef | Web of Science | Medline16
Chalasani NP ,Sanyal AJ ,Kowdley KV , et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2008;30:88-96
CrossRef | Web of Science | Medline17
Kleiner DE ,Brunt EM ,Van Natta M , et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321
CrossRef | Web of Science | Medline18
Skinner HA ,Holt S ,Schuller R ,Roy J ,Israel Y . Identification of alcohol abuse using laboratory tests and a history of trauma. Ann Intern Med 1984;101:847-851
Web of Science | Medline19
Conigrave KM ,Hall WD ,Saunders JB . The AUDIT questionnaire: choosing a cut-off score: Alcohol Use Disorder Identification Test. Addiction 1995;90:1349-1356
CrossRef | Web of Science | Medline20
Powell EE ,Cooksley WG ,Hanson R ,Searle J ,Halliday JW ,Powell LW . The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80
CrossRef | Web of Science | Medline21
Bacon BR ,Farahvash MJ ,Janney CG ,Neuschwander-Tetri BA . Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109
Web of Science | Medline22
Younossi ZM ,Gramlich T ,Liu YC , et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998;11:560-565
Web of Science | Medline23
Ratziu V ,Charlotte F ,Heurtier A , et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906
CrossRef | Web of Science | Medline24
Chalasani N ,Wilson L ,Kleiner DE ,Cummings OW ,Brunt EM ,Unalp A . Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008;48:829-834
CrossRef | Web of Science | Medline25
Hampton T . Diabetes drugs tied to fractures in women. JAMA 2007;297:1645-1645
CrossRef | Web of Science | Medline26
Brunt EM ,Kleiner DE ,Wilson LA , et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology 2009;49:809-820
CrossRef | Web of Science | Medline27
Lutchman G ,Modi A ,Kleiner DE , et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46:424-429
CrossRef | Web of Science | Medline28
Mannucci E ,Monami M ,Lamanna C ,Gensini GF ,Marchionni N . Pioglitazone and cardiovascular risk: a comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008;10:1221-1238
CrossRef | Web of Science | Medline29
Miller ER III ,Pastor-Barriuso R ,Dalal D ,Riemersma RA ,Appel LJ ,Guallar E . Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46
Web of Science | Medline
- Citing Articles (133)
Citing Articles
1
Tuyet A T Nguyen, Arun J Sanyal. (2012) Pathophysiology guided treatment of nonalcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 27, 58-64
CrossRef2
Andrew J. Simpson, Ryan M. Ford. 2012. Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease. , 190-204.
CrossRef3
Danielle B Andrews, Joel E Lavine. (2012) Medical therapy for nonalcoholic fatty liver disease in children and adolescents. Expert Review of Gastroenterology & Hepatology 6:1, 1-3
CrossRef4
Maud Lemoine, Lawrence Serfaty, Jacqueline Capeau. (2012) From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients. Current Opinion in Infectious Diseases 25:1, 10-16
CrossRef5
Ahmad Al-Serri, Quentin M. Anstee, Luca Valenti, Valerio Nobili, Julian B.S. Leathart, Paola Dongiovanni, Julia Patch, Anna Fracanzani, Silvia Fargion, Christopher P. Day, Ann K. Daly. (2012) The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology 56:2, 448-454
CrossRef6
Ali Akbar Hajiaghamohammadi, Amir Ziaee, Rasoul Samimi. (2012) The Efficacy of Licorice Root Extract in Decreasing Transaminase Activities in Non-alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. Phytotherapy Researchn/a-n/a
CrossRef7
G. Musso, M. Cassader, F. Rosina, R. Gambino. (2012) Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia
CrossRef8
Joanna K. Dowman, Phil N. Newsome. 2012. The Chronic Liver Disease Patient. , 174-188.
CrossRef9
Miriam B. Vos, Ryan Colvin, Patricia Belt, Jean P. Molleston, Karen F. Murray, Philip Rosenthal, Jeffrey B. Schwimmer, James Tonascia, Aynur Unalp, Joel E. Lavine. (2012) Correlation of Vitamin E, Uric Acid, and Diet Composition With Histologic Features of Pediatric NAFLD. Journal of Pediatric Gastroenterology and Nutrition 54:1, 90-96
CrossRef10
Federico Salamone, Fabio Galvano, Francesco Cappello, Andrea Mangiameli, Ignazio Barbagallo, Giovanni Li Volti. (2012) Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Translational Research
CrossRef11
E. Boettcher, G. Csako, F. Pucino, R. Wesley, R. Loomba. (2012) Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 35:1, 66-75
CrossRef12
Angela Mazza, Barbara Fruci, Giorgia Anna Garinis, Stefania Giuliano, Roberta Malaguarnera, Antonino Belfiore. (2012) The Role of Metformin in the Management of NAFLD. Experimental Diabetes Research 2012, 1-13
CrossRef13
Eric M. Nelsen, Darrell B. Newman, Seth Sweetser. (2012) 52-Year-Old Man With Liver Enzyme Abnormalities and Elevated Ferritin Level. Mayo Clinic Proceedings 87:1, 94-97
CrossRef14
Detlef Schuppan, Massimo Pinzani. (2012) Anti-fibrotic therapy: Lost in translation?. Journal of Hepatology 56, S66-S74
CrossRef15
Kris V. Kowdley, Patricia Belt, Laura A. Wilson, Matthew M. Yeh, Brent A. Neuschwander-Tetri, Naga Chalasani, Arun J. Sanyal, James E. Nelson, . (2012) Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55:1, 77-85
CrossRef16
Elizabeth M. Brunt, Brent A. Neuschwander-Tetri, Alastair D. Burt. 2012. Fatty liver disease. , 293-359.
CrossRef17
Don C. Rockey, Scott L. Friedman. 2012. Hepatic Fibrosis and Cirrhosis. , 64-85.
CrossRef18
Elizabeth L. Ellis, Derek A. Mann. (2012) Clinical Evidence for the Regression of Liver Fibrosis. Journal of Hepatology
CrossRef19
Stephen H. Caldwell, Curtis K. Argo, Abdullah M. S. Al-Osaimi. 2011. Nonalcoholic Fatty Liver Disease. , 868-907.
CrossRef20
Samer Gawrieh, Miranda C. Marion, Richard Komorowski, James Wallace, Michael Charlton, Ahmed Kissebah, Carl D. Langefeld, Michael Olivier. (2011) Genetic Variation in the Peroxisome Proliferator Activated Receptor-Gamma Gene Is Associated with Histologically Advanced NAFLD. Digestive Diseases and Sciences
CrossRef21
Jörn M. Schattenberg, Detlef Schuppan. (2011) Nonalcoholic steatohepatitis. Current Opinion in Lipidology 22:6, 479-488
CrossRef22
Ali A. Mencin, Joel E. Lavine. (2011) Advances in Pediatric Nonalcoholic Fatty Liver Disease. Pediatric Clinics of North America 58:6, 1375-1392
CrossRef23
W. Nseir, A. Shalata, A. Marmor, N. Assy. (2011) Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease. Digestive Diseases and Sciences 56:12, 3439-3449
CrossRef24
Shefali Agrawal, Cherag Daruwala. (2011) Metabolic syndrome and hepatic resection: improving outcome. HPB 13:12, 846-859
CrossRef25
Giovanni Musso, Maurizio Cassader, Roberto Gambino. (2011) Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease. Current Opinion in Lipidology 22:6, 489-496
CrossRef26
Padma Sathyanarayana, Medhavi Jogi, Raja Muthupillai, Ramkumar Krishnamurthy, Susan L. Samson, Mandeep Bajaj. (2011) Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes. Obesity 19:12, 2310-2315
CrossRef27
Suzanne E. Mahady, Angela C. Webster, Sarah Walker, Arun Sanyal, Jacob George. (2011) The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis. Journal of Hepatology 55:6, 1383-1390
CrossRef28
Federico Salamone, Fabio Galvano, Antonella Marino, Claudia Paternostro, Daniele Tibullo, Fabio Bucchieri, Andrea Mangiameli, Maurizio Parola, Elisabetta Bugianesi, Giovanni Li Volti. (2011) Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Digestive and Liver Disease
CrossRef29
Simona Moscatiello, Raffaella Di Luzio, Anna Simona Sasdelli, Giulio Marchesini. (2011) Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opinion on Pharmacotherapy 12:17, 2657-2672
CrossRef30
Jill A. Parnell, Maitreyi Raman, Kevin P. Rioux, Raylene A. Reimer. (2011) The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Internationaln/a-n/a
CrossRef31
Florence Pietu, Olivier Guillaud, Thomas Walter, Mélanie Vallin, Valérie Hervieu, Jean-Yves Scoazec, Jérôme Dumortier. (2011) Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results. Clinics and Research in Hepatology and Gastroenterology
CrossRef32
Kathleen E. Corey, Naga Chalasani. (2011) Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?. Hepatology 54:5, 1503-1505
CrossRef33
Dawn M. Torres, Frances J. Jones, Janet C. Shaw, Christopher D. Williams, John A. Ward, Stephen A. Harrison. (2011) Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial. Hepatology 54:5, 1631-1639
CrossRef34
Ashwani K. Singal, Sarat C. Jampana, Steven A. Weinman. (2011) Antioxidants as therapeutic agents for liver disease. Liver International 31:10, 1432-1448
CrossRef35
Richard K. Sterling, Arun J. Sanyal. (2011) Pentoxifylline for steatohepatitis: Magic bullet or smoking gun?. Hepatology 54:5, 1496-1499
CrossRef36
N. T. Snider, S. V. W. Weerasinghe, A. Singla, J. M. Leonard, S. Hanada, P. C. Andrews, A. S. Lok, M. B. Omary. (2011) Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation. The Journal of Cell Biology 195:2, 217-229
CrossRef37
Valerio Nobili, Arun J. Sanyal. (2011) Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. Journal of Gastroenterology
CrossRef38
Esther Phielix, Julia Szendroedi, Michael Roden. (2011) The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends in Pharmacological Sciences 32:10, 607-616
CrossRef39
Mark F. McCarty. (2011) Full-spectrum antioxidant therapy featuring astaxanthin coupled with lipoprivic strategies and salsalate for management of non-alcoholic fatty liver disease. Medical Hypotheses 77:4, 550-556
CrossRef40
Mary E. Rinella. (2011) Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?. Hepatology 54:4, 1118-1120
CrossRef41
Matt Cave, Keith Cameron Falkner, Latasha Henry, Brittany Costello, Bonnie Gregory, Craig J. McClain. (2011) Serum Cytokeratin 18 and Cytokine Elevations Suggest A High Prevalence of Occupational Liver Disease in Highly Exposed Elastomer/Polymer Workers. Journal of Occupational and Environmental Medicine 53:10, 1128-1133
CrossRef42
Paul C. Adams. (2011) Chelation Therapy for Secondary Iron Overload: Is the Primary Effect Less Iron or Less Liver Fibrosis?. Gastroenterology 141:4, 1142-1143
CrossRef43
Paola Dongiovanni, Anna Ludovica Fracanzani, Silvia Fargion, Luca Valenti. (2011) Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. Journal of Hepatology 55:4, 920-932
CrossRef44
Giorgio Soardo, Debora Donnini, Liana Domenis, Cristiana Catena, Daniele De Silvestri, Dario Cappello, Alessia Dibenedetto, Alessia Carnelutti, Vincenzo Bonasia, Claudio Pagano, Leonardo A. Sechi. (2011) Oxidative Stress Is Activated by Free Fatty Acids in Cultured Human Hepatocytes. Metabolic Syndrome and Related Disorders 9:5, 397-401
CrossRef45
Andres F. Carrion, Ravi Ghanta, Olveen Carrasquillo, Paul Martin. (2011) Chronic Liver Disease in the Hispanic Population of the United States. Clinical Gastroenterology and Hepatology 9:10, 834-841
CrossRef46
Silvia Sookoian, Tomas Fernández Gianotti, Maria Soledad Rosselli, Adriana L. Burgueño, Gustavo O. Castaño, Carlos J. Pirola. (2011) Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 218:2, 378-385
CrossRef47
Kazushi Sugimoto, Yoshiyuki Takei. (2011) Clinicopathological features of non-alcoholic fatty liver disease. Hepatology Research 41:10, 911-920
CrossRef48
Anne Tailleux, Kristiaan Wouters, Bart Staels. (2011) Roles of PPARs in NAFLD: Potential therapeutic targets. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
CrossRef49
Raj Vuppalanchi, Ravi Juluri, Lauren N. Bell, Marwan Ghabril, Lisa Kamendulis, James E. Klaunig, Romil Saxena, David Agarwal, Matthew S. Johnson, Naga Chalasani. (2011) Oxidative Stress in Chronic Liver Disease: Relationship Between Peripheral and Hepatic Measurements. The American Journal of the Medical Sciences 342:4, 314-317
CrossRef50
Patrick-Olivier Décarie, Luigi Lepanto, Jean-Sébastien Billiard, Damien Olivié, Jessica Murphy-Lavallée, Claude Kauffmann, An Tang. (2011) Fatty liver deposition and sparing: a pictorial review. Insights into Imaging 2:5, 533-538
CrossRef51
Arthur J McCULLOUGH. (2011) Epidemiology of the metabolic syndrome in the USA. Journal of Digestive Diseases 12:5, 333-340
CrossRef52
Helen M. Parker, Nathan A. Johnson, Catriona A. Burdon, Jeffrey S. Cohn, Helen T. O’Connor, Jacob George. (2011) Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology
CrossRef53
Julia Szendroedi, Esther Phielix, Michael Roden. (2011) The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nature Reviews Endocrinology
CrossRef54
Melissa Palmer. 2011. Nutrition and Nonalcoholic and Viral Liver Diseases. , 109-138.
CrossRef55
Ruben Hernaez, Mariana Lazo, Susanne Bonekamp, Ihab Kamel, Frederick L. Brancati, Eliseo Guallar, Jeanne M. Clark. (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology 54:3, 1082-1090
CrossRef56
Romina Lomonaco, Carolina Ortiz-Lopez, Beverly Orsak, Joan Finch, Amy Webb, Fernando Bril, Christopher Louden, Fermin Tio, Kenneth Cusi. (2011) Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology 54:3, 837-845
CrossRef57
Dongsheng Jiang. (2011) Care of Chronic Liver Disease. Primary Care: Clinics in Office Practice 38:3, 483-498
CrossRef58
Neil Parikh, Jawad Ahmad. (2011) Nonalcoholic Fatty Liver Disease: Pharmacologic and Surgical Options. Gastroenterology Clinics of North America 40:3, 541-559
CrossRef59
Roberto Gambino, Giovanni Musso, Maurizio Cassader. (2011) Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities. Antioxidants & Redox Signaling 15:5, 1325-1365
CrossRef60
Mohamed H. Ahmed, Christopher D. Byrne. 2011. Non-Alcoholic Fatty Liver Disease. , 245-277.
CrossRef61
Paul Angulo. (2011) Clinical trials: Trial design in NASH—realities and challenges. Nature Reviews Gastroenterology & Hepatology 8:8, 424-425
CrossRef62
Satish C. Kalhan, John Edmison, Susan Marczewski, Srinivasan Dasarathy, Lourdes L. Gruca, Carole Bennett, Clarita Duenas, Rocio Lopez. (2011) Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. Clinical Science 121:4, 179-189
CrossRef63
Jean Gugenheim, Antonio Iannelli. (2011) What impact does laparoscopic sleeve gastrectomy have on lipid levels in patients with metabolic disease?. Clinical Lipidology 6:4, 353-355
CrossRef64
Shaoyun Wang, Amrita Kamat, Pablo Pergola, Anita Swamy, Fermin Tio, Kenneth Cusi. (2011) Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo. Metabolism 60:8, 1090-1099
CrossRef65
Claudia Della Corte, Anna Alisi, Raffaele Iorio, Arianna Alterio, Valerio Nobili. (2011) Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 12:12, 1901-1911
CrossRef66
J. K. Dowman, M. J. Armstrong, J. W. Tomlinson, P. N. Newsome. (2011) Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 13:8, 692-702
CrossRef67
E. Matthew Morris, R. Scott Rector, John P. Thyfault, Jamal A. Ibdah. (2011) Mitochondria and Redox Signaling in Steatohepatitis. Antioxidants & Redox Signaling 15:2, 485-504
CrossRef68
Fatima Zahra Aly, David E. Kleiner. (2011) Update on Fatty Liver Disease and Steatohepatitis. Advances in Anatomic Pathology 18:4, 294-300
CrossRef69
Frank A. Anania. (2011) Non-alcoholic fatty liver disease and fructose: Bad for us, better for mice. Journal of Hepatology 55:1, 218-220
CrossRef70
Mauro Maurantonio, Stefano Ballestri, Maria Rosaria Odoardi, Amedeo Lonardo, Paola Loria. (2011) Treatment of Atherogenic Liver Based on the Pathogenesis of Nonalcoholic Fatty Liver Disease: A Novel Approach to Reduce Cardiovascular Risk?. Archives of Medical Research 42:5, 337-353
CrossRef71
Vlad Ratziu, Loredana Pienar. (2011) Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones?. Hepatology Research 41:7, 687-695
CrossRef72
Edward Lebovics, Jonah Rubin. (2011) Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes/Metabolism Research and Reviews 27:5, 419-424
CrossRef73
Arun J. Sanyal, Elizabeth M. Brunt, David E. Kleiner, Kris V. Kowdley, Naga Chalasani, Joel E. Lavine, Vlad Ratziu, Arthur McCullough. (2011) Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54:1, 344-353
CrossRef74
J. C. Cohen, J. D. Horton, H. H. Hobbs. (2011) Human Fatty Liver Disease: Old Questions and New Insights. Science 332:6037, 1519-1523
CrossRef75
Briohny W. Smith, Leon A. Adams. (2011) Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences 48:3, 97-113
CrossRef76
Kunihiro Tatsumi, Hideyuki Sasaki, Atsuyo Fujita, Asako Doi, Yumi Kanaya, Hiroto Furuta, Masahiro Nishi, Takuo Tsuno, Hisaji Taniguchi, Kishio Nanjo. (2011) Effect of anti-oxidants, Ricetrienol and α-tocopherol, on adipocytokine abnormalities and fatty liver in Otsuka Long-Evans Tokushima Fatty diabetic rats. Journal of Diabetes Investigation 2:3, 186-192
CrossRef77
Rodolphe Anty, Maud Lemoine. (2011) Liver fibrogenesis and metabolic factors. Clinics and Research in Hepatology and Gastroenterology 35, S10-S20
CrossRef78
Maud Lemoine, Lawrence Serfaty. (2011) Stéatopathies métaboliques. La Presse Médicale
CrossRef79
Briohny W. Smith, Leon A. Adams. (2011) Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nature Reviews Endocrinology 7:8, 456-465
CrossRef80
Rogal, Shari S., Ukomadu, Chinweike, Levy, Bruce D., Loscalzo, Joseph, . (2011) A Sweet Source of Abdominal Pain. New England Journal of Medicine 364:18, 1762-1767
Full Text81
Marion Haedrich, Jean-François Dufour. (2011) UDCA for NASH: End of the story?. Journal of Hepatology 54:5, 856-858
CrossRef82
R. Dohil, S. Schmeltzer, B. L. Cabrera, T. Wang, J. Durelle, K. B. Duke, J. B. Schwimmer, J. E. Lavine. (2011) Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 33:9, 1036-1044
CrossRef83
Giovanni Targher, Michel Chonchol, Giacomo Zoppini, Cataldo Abaterusso, Enzo Bonora. (2011) Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link?. Journal of Hepatology 54:5, 1020-1029
CrossRef84
Samar H Ibrahim, Rohit Kohli, Gregory J Gores. (2011) Mechanisms of Lipotoxicity in NAFLD and Clinical Implications. Journal of Pediatric Gastroenterology and Nutrition1
CrossRef85
Stephen H. Caldwell, Curtis K. Argo. 2011. Non-Alcoholic Fatty Liver Disease and Nutrition. , 546-567.
CrossRef86
Venessa Pattullo, Mark W Douglas, Jacob George. (2011) Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis?. Expert Review of Gastroenterology & Hepatology 5:2, 265-277
CrossRef87
R Christopher Harmon, Dina G Tiniakos, Curtis K Argo. (2011) Inflammation in nonalcoholic steatohepatitis. Expert Review of Gastroenterology & Hepatology 5:2, 189-200
CrossRef88
Amedeo Lonardo, Stefano Bellentani, Vlad Ratziu, Paola Loria. (2011) Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies?. Expert Review of Gastroenterology & Hepatology 5:2, 279-289
CrossRef89
Tomokatsu Miyaki, Shunsuke Nojiri, Noboru Shinkai, Atsunori Kusakabe, Kentaro Matsuura, Etsuko Iio, Satoru Takahashi, Ge Yan, Kazuo Ikeda, Takashi Joh. (2011) Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats. Hepatology Research 41:4, 375-385
CrossRef90
Luigi E Adinolfi, Luciano Restivo. (2011) Does vitamin E cure nonalcoholic steatohepatitis?. Expert Review of Gastroenterology & Hepatology 5:2, 147-150
CrossRef91
Michael Trauner, Emina Halilbasic. (2011) Nuclear Receptors as New Perspective for the Management of Liver Diseases. Gastroenterology 140:4, 1120-1125.e12
CrossRef92
Samuele De Minicis, Gianluca Svegliati-Baroni. (2011) Fibrogenesis in nonalcoholic steatohepatitis. Expert Review of Gastroenterology & Hepatology 5:2, 179-187
CrossRef93
Stephani A. Day, Ashley M. Lakner, Cathy C. Moore, Mao-Hsiung Yen, Mark G. Clemens, Edwin S. Wu, Laura W. Schrum. (2011) Opioid-like compound exerts anti-fibrotic activity via decreased hepatic stellate cell activation and inflammation. Biochemical Pharmacology 81:8, 996-1003
CrossRef94
Giulio Marchesini, Simona Moscatiello, Federica Agostini, Nicola Villanova, Davide Festi. (2011) Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opinion on Emerging Drugs 16:1, 121-136
CrossRef95
Mariko Hojo, Sumio Watanabe. (2011) Pharmacological therapy of nonalcoholic steatohepatitis. Hepatology Research 41:3, 209-216
CrossRef96
Kristin D Kistler, Elizabeth M Brunt, Jeanne M Clark, Anna Mae Diehl, James F Sallis, Jeffrey B Schwimmer. (2011) Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease. The American Journal of Gastroenterology 106:3, 460-468
CrossRef97
Hari S Conjeevaram, Dina G Tiniakos. (2011) Editorial: Exercise for NAFLD: Does Intensity Matter?. The American Journal of Gastroenterology 106:3, 470-475
CrossRef98
John Richard, Ildiko Lingvay. (2011) Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Review of Cardiovascular Therapy 9:3, 321-328
CrossRef99
2011. Type 2 Diabetes: Pharmacological Treatment of Hyperglycaemia. , 102-138.
CrossRef100
Brian Lam, Zobair M Younossi. (2011) Novel treatment strategies for patients with nonalcoholic fatty liver disease. Clinical Investigation 1:2, 229-239
CrossRef101
James E. Nelson, Laura Wilson, Elizabeth M. Brunt, Matthew M. Yeh, David E. Kleiner, Aynur Unalp-Arida, Kris V. Kowdley. (2011) Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 53:2, 448-457
CrossRef102
John FUNG. (2011) Liver transplantation for fatty liver disease. Journal of Digestive Diseases 12:1, 36-37
CrossRef103
Catherine Rongey, Hal F. Yee. (2011) From the bedside to the community: Comparative effectiveness, health services, and implementation research. Hepatology 53:2, 673-677
CrossRef104
Carolina Ortiz-Lopez, Maria L Policarpio-Nicolas, Kenneth Cusi. (2011) Effect of pioglitazone in a patient with impaired glucose tolerance and nonalcoholic steatohepatitis. Diabetes Management 1:1, 33-36
CrossRef105
Jeong Wan Seo. (2011) Nonalcoholic Fatty Liver Disease in Children. Korean Journal of Pediatric Gastroenterology and Nutrition 14:3, 209
CrossRef106
Takeshi Okanoue, Atsushi Umemura, Kohichiroh Yasui, Yoshito Itoh. (2011) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. Journal of Gastroenterology and Hepatology 26, 153-162
CrossRef107
Bianca M Arendt, Johane P Allard. (2011) Editorial: Effect of Atorvastatin, Vitamin E and C on Nonalcoholic Fatty Liver Disease: Is the Combination Required?. The American Journal of Gastroenterology 106:1, 78-80
CrossRef108
A Erhardt, W Stahl, H Sies, F Lirussi, A Donner, D Häussinger. (2011) Plasma levels of vitamin e and carotenoids are decreased in patients with nonalcoholic steatohepatitis (nash). European Journal of Medical Research 16:2, 76
CrossRef109
Vlad Ratziu, Muhammad Y. Sheikh, Arun J. Sanyal, Joseph K. Lim, Hari Conjeevaram, Naga Chalasani, Manal Abdelmalek, Anezi Bakken, Christophe Renou, Melissa Palmer, Robert A. Levine, B. Raj Bhandari, Melanie Cornpropst, Wei Liang, Benjamin King, Elsa Mondou, Franck S. Rousseau, John McHutchison, Mario Chojkier. (2011) A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatologyn/a-n/a
CrossRef110
Jeffrey W. Molloy, Christopher J. Calcagno, Christopher D. Williams, Frances J. Jones, Dawn M. Torres, Stephen A. Harrison. (2011) Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatologyn/a-n/a
CrossRef111
Masafumi Ono, Nobuto Okamoto, Toshiji Saibara. (2010) The latest idea in NAFLD/NASH pathogenesis. Clinical Journal of Gastroenterology 3:6, 263-270
CrossRef112
Liu Yang, Stephen A. Stimpson, Lihong Chen, W. Wallace Harrington, Don C. Rockey. (2010) Effectiveness of the PPARγ agonist, GW570, in liver fibrosis. Inflammation Research 59:12, 1061-1071
CrossRef113
Silvia Sookoian, Maria Soledad Rosselli, Carolina Gemma, Adriana L. Burgueño, Tomas Fernández Gianotti, Gustavo O. Castaño, Carlos J. Pirola. (2010) Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: Impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter. Hepatology 52:6, 1992-2000
CrossRef114
Gerald F Watts. (2010) Nutrition and metabolism: nutritional therapy for disordered triglyceride metabolism and nonalcoholic fatty liver disease. Current Opinion in Lipidology 21:6, 545-547
CrossRef115
Anisha A. Gupte, Joey Z. Liu, Yuelan Ren, Laurie J. Minze, Jessica R. Wiles, Alan R. Collins, Christopher J. Lyon, Domenico Pratico, Milton J. Finegold, Stephen T. Wong, Paul Webb, John D. Baxter, David D. Moore, Willa A. Hsueh. (2010) Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 52:6, 2001-2011
CrossRef116
Vlad Ratziu, Stephen Caldwell, Brent A. Neuschwander-Tetri. (2010) Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues. Hepatology 52:6, 2206-2215
CrossRef117
Jeremy F. L. Cobbold, Quentin M. Anstee, Simon D. Taylor-Robinson. (2010) The importance of fatty liver disease in clinical practice. Proceedings of the Nutrition Society 69:04, 518-527
CrossRef118
M. O. Rakoski, A. G. Singal, M. A. M. Rogers, H. Conjeevaram. (2010) Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 32:10, 1211-1221
CrossRef119
Herbert Tilg, Alexander R. Moschen. (2010) Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52:5, 1836-1846
CrossRef120
Sanjaya K. Satapathy, Arun J Sanyal. (2010) Novel treatment modalities for nonalcoholic steatohepatitis. Trends in Endocrinology & Metabolism 21:11, 668-675
CrossRef121
Hannele Yki-Järvinen. (2010) Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. Current Opinion in Clinical Nutrition and Metabolic Care 13:6, 709-714
CrossRef122
Angel Brea Hernando, José Puzo Foncillas. (2010) Enfermedad del hígado graso no alcohólico y riesgo cardiovascular. Clínica e Investigación en Arteriosclerosis 22:6, 259-271
CrossRef123
Marcin Krawczyk, Leonilde Bonfrate, Piero Portincasa. (2010) Nonalcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology 24:5, 695-708
CrossRef124
Leon A Adams, Ariel E Feldstein. (2010) Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Review of Gastroenterology & Hepatology 4:5, 623-635
CrossRef125
Targher, Giovanni, Day, Christopher P., Bonora, Enzo, . (2010) Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. New England Journal of Medicine 363:14, 1341-1350
Full Text126
(2010) Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine 363:12, 1185-1186
Full Text127
Brent A. Neuschwander-Tetri, Jeanne M. Clark, Nathan M. Bass, Mark L. Van Natta, Aynur Unalp-Arida, James Tonascia, Claudia O. Zein, Elizabeth M. Brunt, David E. Kleiner, Arthur J. McCullough, Arun J. Sanyal, Anna Mae Diehl, Joel E. Lavine, Naga Chalasani, Kris V. Kowdley, . (2010) Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52:3, 913-924
CrossRef128
Quentin M. Anstee, Danilo Concas, Hiromi Kudo, Adam Levene, John Pollard, Peter Charlton, Howard C. Thomas, Mark R. Thursz, Robert D. Goldin. (2010) Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. Journal of Hepatology 53:3, 542-550
CrossRef129
Giovanni Davì, Francesca Santilli, Carlo Patrono. (2010) Nutraceuticals in Diabetes and Metabolic Syndrome. Cardiovascular Therapeutics 28:4, 216-226
CrossRef130
Massimo Pinzani, Jose Macias-Barragan. (2010) Update on the pathophysiology of liver fibrosis. Expert Review of Gastroenterology & Hepatology 4:4, 459-472
CrossRef131
Jean-François F. Dufour, Kris Kowdley, Geoffrey McCaughan, Christian Trautwein. (2010) Vitamin E for nonalcoholic steatohepatitis: Ready for prime time?. Hepatology 52:2, 789-792
CrossRef132
Claire Greenhill. (2010) Vitamin E—therapy for NASH?. Nature Reviews Gastroenterology & Hepatology 7:7, 361-361
CrossRef133
Jae Sung Ko. (2010) Nonalcoholic Fatty Liver Disease. The Korean Journal of Gastroenterology 56:1, 6
CrossRef
- Letters
